Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, High-Dose Cyclophosphamide, and KGEL Vaccine for Relapsed Hodgkin's Lymphoma
NCT00134082Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2005
- Primary completion
- Jan 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GM-K562 in Hodgkin lymphoma (HL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2005; status: completed.
02
Drugs
GM-K562
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00134082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134082.